biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Saltarelli is in the catbird seat...

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jan 10, 2023 8:14am

120 Views

Post# 35212907

RE:Saltarelli is in the catbird seat...

prophetoffactz wrote: And he's looked under the hood of Biodexa in ways that we wil never be able to.

The asset's clinical and near-clinical assets have markets of $12 billion. It also have multiple platform technolgies with J&J investigating two of them. Armistice Capital and Ladenberg Thalmann are on board. And look at the curret market cap and potential in 18 months alone? WAKE UP!

Saltarelli is in the catbird seat!

"Saltarelli is in the catbird seat", without owning a single common share, according to SEDI. I wonder why.

Plenty of granted options though, 1,378,217.

G1945V

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment